

FAX FORM AND CLINICAL DOCUMENTATION

## ANALGESICS, NON-OPIOID BARBITURATE COMBINATIONS

## PRIOR AUTHORIZATION FORM (form effective 1/6/2025)

Prior authorization guidelines and Quantity Limits/Daily Dose Limits are available on the DHS Pharmacy Services website at <a href="https://www.pa.gov/en/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.html">https://www.pa.gov/en/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services.html</a>.

New request Renewal request	Total # of pgs:	Prescriber name:		
Name of office contact:		Specialty:		
Contact's phone number:		NPI:	State license #:	
LTC facility contact/phone:		Street address:		
Beneficiary name:		City/state/zip:		
Beneficiary ID#:	DOB:	Phone:	Fax:	

## **CLINICAL INFORMATION**

Drug requested:			Strength:		
Dosage form (tablet, capsule, etc):	Quantity:	per	days	Refills:	
Directions:					
Diagnosis:		Dx code ( <u>requ</u>	<u>uired</u> ):		
Complete the sections below that are applicable to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.					
<ul> <li>1. For ALL requests:</li> <li>Is not taking primidone or any other drug(s) containing a b</li> <li>Will not take the requested drug on more than 3 days per</li> <li>Has a diagnosis of headache based on the current Interna</li> <li>Has a history of trial and failure of or a contraindication or headache based on headache classification:</li> <li>acetaminophen</li> <li>analgesic/caffeine combinations (e.g., Excedrin)</li> <li>NSAIDs</li> <li>other:</li> </ul>	month ational Headache Societ	ty Classificatio			





## FAX FORM AND CLINICAL DOCUMENTATION

2.	For a beneficiary 65 YEARS OF AGE OR OLDER:
	The benefits of the requested drug outweigh the increased risks based on the prescriber's assessment
	Was counseled by the prescriber regarding the potential increased risks of the requested drug
3.	For the treatment of CHRONIC DAILY HEADACHE (presence of headache on 15 or more days per month for at least 3 months):  Secondary causes of headache ruled out based on a physical exam Secondary causes of headache ruled out based on a complete neurological exam
	Was evaluated for the overuse of abortive drugs for the treatment of headache, including acetaminophen, butalbital, caffeine, NSAIDs, opioids, and triptans
	Was counseled regarding behavioral modifications, such as cessation of caffeine and tobacco use, improved sleep hygiene, dietary changes, and regular mealtimes
	Is currently taking preventive drug therapy based on headache classification or has a contraindication or an intolerance to preventive drug therapies:
	Itricyclic antidepressants (e.g., amitriptyline, nortriptyline, protriptyline)
	Other antidepressants (e.g., mirtazapine, SNRIs [e.g., venlafaxine])
	anticonvulsants (e.g., gabapentin, topiramate)
	tizanidine (Zanaflex)
	other:
	Was counseled regarding the potential adverse effects of the requested drug, including the risk of medication overuse headache, misuse, abuse, and addiction
	Has a history of substance use disorder AND:
	Has results of a recent urine drug screen testing for licit and illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol) that is consistent with prescribed controlled substances
4.	For a NON-PREFERRED Analgesic, Non-Opioid Barbiturate Combination:
	Has a history of trial and failure of or a contraindication or an intolerance to the preferred Analgesics, Non-Opioid Barbiturate Combinations that are approved or medically accepted for treatment of the beneficiary's diagnosis ( <i>Refer to</i> <u>https://papdl.com/preferred-drug-list</u> for a list of preferred and non-preferred drugs in this class.)
	PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO 866-240-3712

Prescriber	Signature:

Date:

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.